Industry & Pharma feed

View Event

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026

Data show long-term effectiveness of GARDASIL®9 and GARDASIL® 14 years and 18 years, respectively, f...

Our Commitment to the Hemophilia B Community: An Update on HEMGENIX® (etranacogene dezaparvovec-drlb) Availability

View latest results

Human, AI, robots: Co-creating cell therapy

Astellas & YASKAWA's joint venture, Cellafa, uses AI and a humanoid robot to revolutionize cell ther...

SmallCap Event 20th Edition

Women Winemakers of Sonoma & Napa: Q&A with the Women Behind the Wines

March is International Women’s Month! We’re celebrating female empowerment with a fun Q&A with the w...

Allergan Aesthetics Redefines Skin Quality Communication with Launch of Skin Quality Index

Research published in Dermatologic Surgery identifies inconsistencies in how patients and providers...

Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis

In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement ( EASI -75) an...

Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluoroura...

March 16, 2026

Late-breaking presentation of results from the Phase 3 CORALreef AddOn trial evaluating enlicitide d...

Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutionsMarch 16, 2026

With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s l...

Finerenone meets primary endpoint in pivotal Phase III FIND-CKD study in patients with non-diabetic chronic kidney disease

Finerenone significantly delayed kidney disease progression in patients with non-diabetic chronic ki...

Idorsia announces management change

Idorsia Ltd is listed on the SIX Swiss Stock exchange, we provide an archive of our media releases o...

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Atara delivers significant operational efficiencies and extends cash runway through year-end 2026 A...

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Lebrikizumab delivered significant skin clearance and improved disease severity in children with moderate-to-severe atopic dermatitis

ADorable-1 met co-primary efficacy endpoints, with 63% of paediatric patients achieving meaningful s...

20 Feb, 2026VIDEOBB Biotech 2025 Video UpdateFind out more

BB Biotech 2025 Video Update In this short video statement, Dr. Christian Koch, Head BB Biotech Team...

24 Feb, 2026EXPERT COMMENTARYFrom innovation to value realization: The biotech market in a new phaseFind out more

After several years characterized by elevated capital costs, valuation pressure and pronounced risk...

28 Jan, 2026VIDEOExecutive interview with Edison TVFind out more

Executive interview with Edison TV In this video, Dr Koch discusses the increasingly positive sentim...

13 Mar, 2026VIDEOWhy biotech is becoming attractive to investors againFind out more

Navigate to page BB Biotech AG BB Biotech AG (SIX) (CHF) ISIN-No.: CH0038389992 YTD: 2.56% Active sh...

13 Mar, 2026VIDEOBB Biotech – Active management across the biotechnology value chainFind out more

Navigate to page BB Biotech AG BB Biotech AG (SIX) (CHF) ISIN-No.: CH0038389992 YTD: 2.56% Active sh...

Press releaseMar 13, 2026Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativaCosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring…

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mec...

13 March 2026GSK’s RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18–49 years at increased riskIn the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection

บริษัท อมรินทร์ คอร์เปอเรชั่นส์ จำกัด (มหาชน) และกลุ่มบริษัทในเครือ ร่วมเป็นเจ้าภาพบำเพ็ญพระราชกุศลถวายพระบรมศพ ณ พระที่นั่งดุสิตมหาปราสาท

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial ResultsMar 13, 2026

Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in d...

Otsuka Unveils New Repinatrabit Open-Label Extension Data in Phenylketonuria (PKU) Signaling Efficacy in Adolescents at the 2026 American College of Medical Genetics and Genomics (ACMG) Meeting

Otsuka Unveils New Repinatrabit Open-Label Extension Data in Phenylketonuria (PKU) Signaling Efficac...

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

eXoZymes’ CCO Damien Perriman to Present a NCT solution at next week’s MISTA Symposium

Los Angeles, CA -- March 12, 2026 -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of...

ORYZON expands patent protection for iadademstat with grant decision in Mexico covering combinations with PD-1/PD-L1 inhibitors

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Re...

An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12

Lilly is issuing a public warning about potential safety risks associated with compounded tirzepatid...

Mar 12, 2026 6:30 AM EDTXOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

News and Media Center

InflaRx to Report Full Year 2025 Results on March 19, 2026

Bavarian Nordic Launches Next Tranche of Share Buy-Back Program

Bavarian Nordic Publishes Annual Report 2025

Read Release

The AMBAR ® Center in Barcelona reinforces its position as a clinical reference and training center...

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

Indivior Announces Proposed Convertible Senior Notes Offering

All News Releases

Almirall inaugurates offices in China to advance innovation in medical dermatology through partnerships

The biopharmaceutical company’s presence in Shanghai, China is dedicated to life science innovation...

Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow

Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2...

Best Places to Shop Local in Sonoma County

Ditch the mall. Here are the best places to find gifts in Sonoma County so that you can shop local a...

Launch of Joint Sales of the QuickNavi™-Campylobacter Antigen Diagnostic Kit in Japan

Launch of Joint Sales of the QuickNavi™-Campylobacter Antigen Diagnostic Kit in Japan

United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine

The actual press release articles

Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement

Mar.11.2026R & DVertex Announces Positive Week 36 Interim Analysis Results from the Global RAINIER Phase 3 Trial of Povetacicept

Osaka, Japan, March 11, 2026 – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President a...

New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder

Jefferies “Biotech on the Beach” Summit

Change Guerbets Board Directors 0

2025 Full Year Results

10 March 2026GSK tops Antimicrobial Resistance (AMR) Benchmark ReportGSK welcomes independent recognition of our leadership in addressing the urgent global threat of antimicrobial resistance (AMR).

Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec”...

ロシュ社によるギレデストラント酒石酸塩に関する発表について（第III相persevERA試験結果）

中外製薬株式会社 （本社：東京、代表取締役社長 CEO：奥田 修）は、ロシュ社が3月9日に、選択的エストロゲン受容体分解薬ギレデストラント酒石酸塩のホルモン受容体陽性の局所進行または転移性乳がんを対象...

Roche Annual General Meeting 2026March 10, 2026

Shareholders approved all proposals of the Board of Directors Severin Schwan re-elected as Chairman...

Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink

Idorsia Ltd is listed on the SIX Swiss Stock exchange, we provide an archive of our media releases o...

Alnylam to Webcast TTR Investor Webinar

Alnylam to Webcast TTR Investor Webinar

Orion Corporation: Managers’ transactions – Satu Ahomäki3/10/2026 Managers transactions

ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET

Orion Corporation: Managers’ transactions – Hao Pan3/10/2026 Managers transactions

ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET

Orion Corporation: Managers’ transactions – Niclas Lindstedt3/10/2026 Managers transactions

ORION CORPORATION MANAGERS’ TRANSACTIONS 10 MARCH 2026 at 17.00 EET

Orion Corporation: Transfer of 172,778 own B shares on 10 March 20263/10/2026 Stock exchange release

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES 10 MARCH 2026 at 13.50 EE...

March 10, 2026World Kidney Day: Doctors Stress Early Detection as Diabetes and Hypertension Drive Rising Kidney Disease in IndiaRead More

On the occasion of World Kidney Day, Mankind Pharma, in association with leading healthcare experts,...

Preparing our colleagues for the future of work

07 Nov, 2025Turning milestones into momentumFind out more

Back to overview Turning milestones into momentum The latest Edison Research analysis on BB Biotech,...

28 Oct, 2025EXPERT COMMENTARYFourth M&A transaction highlights portfolio strengthFind out more

Novartis has announced yesterday the acquisition of our portfolio company Avidity Biosciences , a pi...

CVS Health Foundation invests $2.24 million to expand community‑based care through Health Impact Ohio

Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference

CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Re...

Updated: Lilly’s Statement on the CMMI BALANCE Model for GLP-1 Medicines and Medicare GLP-1 Bridge Model

Today, the Centers for Medicare and Medicaid Services issued new implementation details for the Medi...

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

ABBV-295 treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-s...

GSK and Alfasigma announce agreement on worldwide rights for linerixibat

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Re...

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

- Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-3...

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBC...

中外製薬、「健康経営銘柄」に3年連続で選定

中外製薬株式会社 （本社：東京、代表取締役社長 CEO：奥田 修）は、特に優れた健康経営を実践している上場企業として経済産業省および東京証券取引所より「健康経営銘柄2026」に選定されましたので、お知...

New and Improved Calorie Mate JELLYEnhanced Taste and Balanced Nutrition, Now Even More Accessible

New and Improved Calorie Mate JELLYEnhanced Taste and Balanced Nutrition, Now Even More Accessible

Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (tras...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancerMarch 09, 2026

persevERA Breast Cancer study did not meet the primary objective of a statistically significant impr...

Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026

United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program

The actual press release articles

CSL announces expansion of Illinois plasma therapy manufacturing facility

Subscribe to Press release email alerts

Sign up for BMY email alerts and receive timely updates on press releases.

Leerink Global Healthcare Conference

Astellas and Hovon Confirm Phase 3 Study Did not Meet its Primary Endpoint of Overall Survival in Patients with Newly DiagnosedFLT3m+ AML

Explore Astellas’ global press releases and discover the latest news and updates about Astellas.

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update

Potential best-in-class profile, including ~1,400-fold selective binding to MTA-PRMT5 versus SAM-PRM...

Leerink Partners Global Healthcare Conference

Mar.09.2026SustainabilityOno Pharma Selected as "2026 Health & Productivity Stock"

Selected for the Health & Productivity Stock for the third time Certified as a Health & Productivity...

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine p...